NCT03857165View on ClinicalTrials.gov

Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 24, 2018

Primary Completion Date

June 2, 2019

Study Completion Date

October 31, 2019

Conditions
Gout, Hyperuricemia
Interventions
DRUG

SAP-001

SAP-001 or placebo treatment in a 3:1 randomization ratio.

Trial Locations (3)

27265

High Point Clinical Trials Center, High Point

32720

Avail - Accel Research Sites, DeLand

92801

Anaheim Clinical Trials, LLC, Anaheim

All Listed Sponsors
lead

Shanton Pharma Co., Ltd.

INDUSTRY

NCT03857165 - Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients | Biotech Hunter | Biotech Hunter